FDA Approves Otsuka’s VOYXACT (Sibeprenlimab-szsi): A Breakthrough in Primary Immunoglobulin A Nephropathy Treatment
The pharmaceutical landscape for immunoglobulin A nephropathy (IgAN) treatment has reached a significant inflection point with the FDA’s accelerated approval of VOYXACT (sibeprenlimab-szsi) on November 25, 2025, for the reduction of proteinuria in adults with primary IgAN at risk for disease progression.
